13 funding opportunities found in this category. Change the order of results: Newest First Oldest First Expiring Soonest Expiring Latest Lowest Award to Highest Highest Award to Lowest
American Orthopaedic Society for Sports Medicine Young Investigators Grant
The Young Investigator Grant provides awards in amounts of up to $40,000 aimed at providing "seed money," or start-up funds, for pilot projects. The principal investigator must be an early career orthopaedic surgeon, fellow, or resident with interests in sports medicine research. Any investigational team seeking such a grant must include at least one member of AOSSM in good standing.
All information should be submitted in one pdf document to Bart Mann, AOSSM Director of Research.
Pre-reviews: In an effort to improve the quality and competitiveness of submissions, the AOSSM Research Committee will pre-review and critique applications prior to the final application deadline. This pre-review is STRONGLY RECOMMENDED but not required. It is anticipated that by participating in the pre-review process, the applicant's chances for funding will improve.
The pre-review will focus on:
Significance of proposed research Scientific quality Statistical methods Realistic nature of goals Long term value of results Pilot data
Submit your application by August 15th to receive a pre-review. You do not need to include any signatures for pre-review.
Note: Final submission deadline: December 1st before midnight. Please contact Bart Mann with any questions.
Autism Speaks Request for Applications: Treatment Research Grants: Full- and Pilot-Level 2012 Cycle
Letter of Intent due: February 23, 2012, 8:00 PM Eastern Autism Speaks invites both Full- and Pilot-Level Treatment research grant applications to conduct innovative clinical studies of novel interventions for individuals with Autism Spectrum Disorders (ASD) throughout the lifespan. These may include medical approaches including complementary and alternative forms of health care and pharmacological treatments, as well as behavioral and/or psychosocial interventions, and evaluation of the efficacy, safety or therapeutic benefits of all types of interventions. Also appropriate are animal model studies that test the effects of novel compounds for reducing autism symptoms.
For all RFAs, Autism Speaks is focusing on a set of targeted research priorities for 2012. All treatment study projects will be required to demonstrate direct relevance to at least one of these targeted research priorities:
1. Understand environmental risk factors and their interaction with genetic susceptibility to enable prevention and improve diagnosis and treatment
2. Discover biomarkers that can improve risk assessment and subtype stratification that will allow for an individualized approach to treatment
3. Improve quality of life through more effective medicines, behavioral interventions, and technologies
4. Enhance diagnosis and treatment of underserved and under-studied populations, specifically,
• Nonverbal persons with ASD • Ethnically-diverse and/or low resource communities • Adults • Those with medical co-morbidities
5. Disseminate and implement evidence-based clinical practices to the broader community worldwide IMPORTANT: The relevance of the proposed research to ASD and Autism Speaks’ research priority areas must be explicitly described in the Letter of Intent (LOI) and full application.
Awards Autism Speaks will make a limited number of treatment research grants determined by the available financial resources. Full-level research grant 1-3 years $150,000/year maximum
Pilot-level research grant 1-2 years $60,000/year maximum
Autism Speaks utilizes a web-based application system for their grant submissions. All applications must be submitted through this system. It is imperative to indicate whether the submission is for the Full- or Pilot-Level Treatment research option.
Research Inquiries research@autismspeaks.org
American Academy of Otolaryngic Allergy Foundation Research Grant
Next Grant Deadline: December 30th
Funding available for targeted studies and pilot projects.
Contact Matt Smith for application details (meetings@aaoaf.org)
American Academy of Implant Dentistry Research Foundation Research Grants Program
The American Academy of Implant Dentistry Research Foundation (AAIDRF) Research Grants Program is intended to provide limited support for meritorious dental implant research projects which include, but are not limited to, the following purposes:
• To conduct research which determines the feasibility of a larger research project. This may be described as the conduct of pilot studies of venture research. • To develop and test new techniques and procedures. • To carry out a small clinical or animal research project. • To analyze existing data.
Eligibility Investigators from any scientific discipline and at any stage of their career may apply for a grant. These awards are appropriate for new investigators and those changing areas of research or resuming research careers.
The proposed project may be related to, but the aims must be distinctly different from, those of pending grant applications. The request may be used to supplement projects currently supported by Federal or non-Federal funds or to provide interim support for projects under review.
Applicants may request up to $25,000 (total costs) for the entire budget to fund the project for up to a two-year grant period. Successful applicants who require additional time to perform the proposed research may request extensions of the grant period without additional funds. This grant is not renewable; however, grantees under this program are encouraged to apply for a regular Research Project Grant to a Federal agency, e.g., the National Institutes of Health, the National Science Foundation, the Veterans Administration, or the Department of Defense, to maintain continuity in their studies.
The Foundation reserves first right of refusal on all papers resulting from the approved/funded project.
Applications received by August 1 will be considered for award announcement at the AAIDRF Annual Meeting. Funding of approved projects will begin on January 1 of the following year.
Please submit application to:
Afshin Alavi AAID Research Foundation 211 E. Chicago Avenue, Suite 750 Chicago, IL 60611 Telephone: (312)335-1550 afshin@aaid.com
Call for Applications: American Academy for Cerebral Palsy and Developmental Medicine Research Grant Award
Deadline: Monday, April 2, 2012
A key mission of the Academy is to promote excellence in research for the benefit of persons with cerebral palsy and childhood-onset disabilities. One way in which the Academy promotes research is through the annual AACPDM Research Grant.
The AACPDM Research Grant Award provides seed funding to develop a high quality clinical research project/program. The award is expected to produce a competitive interdisciplinary, multi-investigator/center grant proposal for submission to larger agencies/funders of research in any area relevant to the AACPDM. Any member of the AACPDM is eligible to apply. Only one grant application per member will be considered in a given budget year. The budget limit is US $25,000 (subject to approval by the Board, which reserves the right to amend the amount awarded).
Successful applicants are expected to take up the award within one month of the annual AACPDM meeting where the award is announced. The funds must be spent within 18 months. Applicants unable to meet this timeframe will forfeit the grant but will be eligible to re-apply in a subsequent year. Unspent funds after 18 months are expected to be returned to the AACPDM.
Use of Funds The award may be used to fund any of the elements necessary to develop the full grant proposal. These may include costs for:
Teleconferences or meetings of the collaborating team of investigators to plan and develop the research protocol including study design, outcome measures, recruitment strategies, data collection and management, analysis, etc Methodologic/Statistical support or consultation Preparation of application/s for institutional ethics approval Support for investigators time Pilot project/feasibility study in preparation for multi-center project Validation of outcome measures intended for multi-center project
The funds are not intended for:
Institutional indirect costs Purchase of personal computers or equipment Stipends or fees for students or post doctoral fellows
AACPDM Office 555 East Wells, Suite 1100 Milwaukee, WI 53202 Phone: 414.918.3014 Fax: 414.276.2146 Email: info@aacpdm.org URL: www.aacpdm.org Office Hours: 8:00 am - 5:00 pm CST
Alliance for Lupus Research 2012 Grant Application Announcment
The Alliance for Lupus Research (ALR) is pleased to announce that the applications for the ALR’s Functional Genomics and Molecular Genetic Pathways in SLE grants are now available online.
Research Grants: Approved grant applications will be eligible to receive a 2-year award for up to $350,000 USD (up to $175,000 USD per year for two years). Research grants must provide evidence of preliminary data.
Pilot Grants: Approved grant applications will be eligible to receive a 1-year award for up to $75,000 USD. Pilot grants are for projects that are not supported by preliminary data. Guidelines for application and submission are also available on the websites listed above.
Deadlines associated with this grant program are as follows:
Grant Applications: Due to ALR by February 15, 2012
Applications submitted should focus on two principal areas: (1) functional validation to determine which candidate genes/variants identified in human lupus have an authentic role in the disease and (2) detailed elucidation of the molecular pathways modulated by these candidate genes/variants identified in human lupus.
There are public resources available to facilitate functional validation of genes/variants involved in lupus. ALR encourages investigators to take advantage of all of these resources. All proposals submitted must be based on information in the public domain.
Responsive applications will propose research to elucidate the functional implications of the genetic variants identified in human lupus studies. Lupus-associated genes studied in animal models that are not among those also identified in human studies are not appropriate topics for this grant mechanism.
ALR will focus support on:
Human Studies: Functional validation studies could use human DNA samples from phenotypically well-characterized individuals to correlate a gene variant with a particular phenotype. Such human studies are particularly encouraged.
Genetic Models: Established genetic models as well as emerging genetic models can be used to look at in vivo gene/variant function.
RNA interference: RNAi depletion of candidate genes in cells, tissues or whole organisms can be used to identify phenotypes.
Imaging strategies: Imaging of cell trafficking in vivo might be useful in characterizing the impact of lupus-associated gene variants on immune responses or inflammation.
Systems-level approaches: Bioinformatic resources (i.e., interactome, gene expression, proteomic, metabolomic, and anatomical databases) can be mined to generate testable hypotheses concerning the function of candidate genes and groups of genes.
Cellular or circuit-level approaches: Studies might compare gene/variant functional consequences at the cellular and circuit levels, especially with respect to a drug challenge.
Epigenetics: Functional validations of epigenetic mechanisms of gene regulation in the context of lupus, including potential maternal and paternal imprinting or X chromosome inactivation, are of interest.
Comparison of wild type and gene variant functions: The molecular alteration associated with a gene variant frequently does not reveal whether the function of a particular gene is increased, decreased, or leads to unexpected functional consequences. Approaches using in vivo transgenes, in vitro biochemical assays, or other validation methods that can address these issues will help to identify the most promising molecular targets for therapeutic interventions.
Identification of functionally significant sequences in disease-associated genomic regions: While some genomic regions show strong statistical association with a diagnosis of SLE, in many cases the specific sequences responsible for the association have not yet been identified. Deep sequencing approaches can be used to define the specific regulatory or coding sequences responsible for the association with SLE and their impact on cell function.
Application Requirements
Applications are open to investigators working at established research institutions (both for profit and not-for profit) as well as investigators at state health agencies, the FDA, VA and at intramural divisions of NIH. Applications may be submitted by investigators working anywhere in the world. Non-U.S. applicants whose projects involve human subjects must work at institutions that have human subjects committees that operate in a substantially similar manner to a U.S. Institutional Review Board.
If you have any questions or require any additional information regarding the application process, please contact Diomaris Gonzalez, Assistant Director of Research Administration at (212) 218-2840; 1-800-867-1743 or at research.admin@lupusresearch.org.
Request for Proposals: Dana Foundation Program in Brain and Immuno-Imaging--Using Brain and Immune Imaging Innovations to Improve Human Health
Application Deadline: Tuesday, February 28th, 2012 at Noon
The Dana Foundation’s imaging research program focuses on improving human brain and brain-immune functioning in health and disease. Funds support pilot-testing by investigators who are early in their research careers of promising but high-risk innovative ideas that have direct clinical application and that, when successful, are competitive for larger-scale support from other funders. Grant amounts may be up to $200,000 total, payable over three years. Applicants will be informed within 14 weeks on whether they will be invited to prepare full proposals. The first awards will be announced in September 2012. Any subsequent award announcements will be made in December 2012. Below is a description of the program and application process.
Please note that this will be the only proposal solicitation process this year, and selection will be extremely competitive, with fewer than 10 percent of preliminary proposals likely to receive funding.
This program, as in all Dana research programs, is oriented to the human. Submitted proposals, therefore, should focus on imaging in patients or patient tissues, and healthy volunteers.
Applications for animal model studies of brain conditions or injuries will be considered only if they relate directly to the human but cannot yet feasibly be undertaken in humans, and are anticipated to be translated into the human following the three-year grant period. Such studies that are not undertaken in humans but directly relate to the human include research on: 1) normal brain anatomy and physiology in the animal model that can help to better understand the roles of cells and networks in specific cognitive functions and how these are altered by disease and injury; and 2) animal models of human diseases, either through insertion of human genes or through naturally occurring or induced disease states, that are directly related to the human condition. Specific criteria for these types of studies are listed in the section on Eligibility.
Previously funded studies under this Program have focused primarily on 1) understanding normal brain functioning, how it is altered by disease or injury, and how it recovers or repairs, 2) assessing and improving diagnostic and therapeutic approaches, and 3) refining and advancing imaging technologies to address specific clinical questions. In addition to these three general areas of continued interest, it is becoming increasingly apparent that neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, and mental illnesses such as schizophrenia and depression start long before they are clinically evident. The Foundation, therefore, encourages studies that seek to understand developmental processes of disease, surrogate measures of early disease existence, and measures of disease progression. Also, for chronic traumatic encephalopathy and Alzheimer’s disease, the role of tau is becoming of increasing interest and the Foundation is receptive to considering studies on how to image tau.
The Foundation invites submission of one preliminary application per invited institution (see eligibility), using either:
• Physiological and Structural imaging - anatomical imaging of white or gray matter and measures of physiological functioning. These proposed studies should focus on patient-oriented clinical research. • Cellular/molecular imaging - biochemical actions of specific brain cells, or their interactions with immune cells, which have direct clinical relevance to human health and disease. These studies may involve human tissues or animal models. Applications can involve the study of cells within neural circuits, using a combination of imaging and single cell electrical recording, if the techniques have already been developed.
Eligibility:
Each U.S. medical school dean, and the presidents of the few selected biomedical research institutions that have been invited by letter, may nominate one applicant. The applicant may use either physiological/structural or cellular imaging or both. To be considered under this Program, the application must be countersigned by the medical school dean or invited biomedical institute’s president.
Investigators at institutions that are affiliated with a medical school are eligible to apply only through their affiliated medical school, by submitting an application to the medical school dean. Previous applicants are eligible to reapply through their dean’s office (or biomedical research institutes’ presidents’ offices). Projects involving collaborations with NIH intramural researchers or industry scientists are acceptable.
Support is focused on faculty researchers who have demonstrated the potential for independent research careers who are at the assistant professor level, or in the first few years of their associate professor appointments. Post-doctoral fellows are not eligible to apply. Applications from junior investigators that are an extension of the work of a senior mentor, particularly if from the same institution, are discouraged.
Funding of up to $200,000 payable over three years is provided for structural/physiological or cellular imaging proposals from promising early career investigators who have not yet been awarded more than one independent research grant (R01 from the NIH or equivalent from another Federal agency).
The Foundation does not provide support for indirect costs. Instead, however, up to 10 percent of the total grant award may be used to purchase equipment for the study. The balance is to be used to meet direct research costs. Studies should be designed to obtain meaningful data within the grant award period of up to three years.
All applicants please note:
All proposals that seek to develop new imaging techniques or assays, or modify existing ones to address clinical questions, whether in structural/physiological or cellular/ molecular imaging, must provide preliminary evidence of feasibility and evidence of the investigator’s experience in using the technology. Proposals seeking support without such preliminary evidence will not be considered.
Investigators proposing patient-oriented studies should provide preliminary evidence that the required number of participants—patients and controls—are available at the research institution(s) involved.
For all proposals that do not propose to undertake studies in humans, the direct relevance to human health and functioning needs to be explicitly stated. These proposed studies will only be considered if they are designed to: 1) pose a specific question concerning the disease process that is directly related to known aspects of brain pathology seen in the human; 2) alter a factor in a healthy animal for which there is some evidence of the factor’s involvement in a human disease process (as opposed to altering a factor in a healthy animal to see if the result resembles a human brain disease); and 3) be translated into studies in the human following the three-year grant period.
Certain areas are not appropriate for consideration:
• Ideas for which you do not have preliminary data. • Instrument development without initial evidence of feasibility and clinical applicability.
Descriptions of all previously funded studies are available at: http://www.dana.org/grants/imaging/.
Applying:
The Program is designed to enable investigators to obtain pilot data more quickly than is possible through other funding processes. Investigations must be applicable to human brain or brain-immune functioning or malfunctioning to be considered for funding. Research that can be supported through clinical income should not be submitted.
The application should be in the form of a four-page preliminary proposal, using at least 11-point font size (font sizes smaller than that will not be reviewed) and .5 inch margins in all directions with numbered pages, consisting of the following:
Page 1:
On institutional letterhead: Please provide a cover page containing all of the following. Write “The Dana Foundation Program in Brain and Immuno-imaging”, followed by: Project title; investigator(s) name(s), title(s), phone and fax numbers, E-mail, and street addresses. Indicate the imaging category (structural/physiological or cellular/molecular, or a combination of both) and, specify the imaging technique(s) (such as fMRI, two-photon, etc). In addition, please include the names and full addresses of the sponsored research officer and the dean or president forwarding the application. All proposals must be countersigned by the dean of a U.S. medical school or president of a specifically invited research institution to be considered eligible.
Pages 2-4: Section I: A clearly and succinctly stated hypothesis. Section II: The aims of the proposed research project. What disease(s), disorder(s) or injuries would be better understood, diagnosed, or treated? Or, what normal brain function or brain-immune interaction would be better understood? Or, what imaging technology would be refined and for what specific purposes? Such technology development or modification aims need to be accompanied by initial evidence of the project’s feasibility. Section III: The research significance and potential clinical application(s) of the research.
Section IV: The methods. Please clearly describe the research design and specify specific tests and analyses proposed to develop the pilot data. If enrollment of human participants is planned, please provide preliminary evidence that the number required can be recruited from the participating institution(s).
Section V: The qualifications of the primary investigator(s) for undertaking the proposed research. What facilities and resources at the applicant institution(s) would be used in the research? Please provide evidence that required technologies would be available for this project.
Additional Pages:
Appendix A: A list of all active grants and pending proposals by the applicant(s). Please include an abstract that specifies the aims for any existing or pending grants from these sources of support that are related to, or could potentially overlap with, the proposed Dana study.
Appendix B: Please provide a standard NIH four-page format CV for the primary investigator(s). Appendix C: Optional: If high resolution photographs are vital to illustrate or support the methodology proposed, please enclose 10 glossy originals. You may include up to two additional pages to list relevant references.
Please note: At this time, do not send a budget, or any other supporting documents.
Proposal Review and Notification of Grant Awards:
Preliminary proposals received by the February 28, 2012, deadline will be reviewed for further development. Late submissions will not be considered. Applicants will be informed within approximately fourteen weeks from preliminary proposal receipt on whether or not they are being invited to prepare full proposals. Please note below the Dana Foundation’s current address.
Grants will be awarded on a “rolling” basis, with the first group of approved studies to be announced in September 2012 and the second group to be announced in December 2012.
Please refer to the FAQ’s section of the Dana Foundation Web site www.dana.org/grants for any questions you may have regarding the proposal process.
The original application and ten copies, each stapled, should be sent to:
Angie Marin Program Associate The Dana Foundation 505 Fifth Avenue, 6th floor New York, NY 10017
Staff is unable to respond to inquiries regarding application content.
Call for Applications: Scleroderma Foundation Established Investigator Grant
Grant Application Deadline: Sept. 15th annually by 5 p.m. EST
If the 15th falls on a Sat. or Sun., then the following Monday at 5 p.m. EST will be the deadline.
Purpose: The Scleroderma Foundation is seeking applications from promising established investigators both inside and outside the field of SSc research who wish to propose pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to SSc. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal or non-federal sources.
Eligibility Requirements: Applications may be submitted by domestic non-profit organizations, public and private such as universities, colleges, hospitals and laboratories. Foreign organizations and institutions are eligible. Applicants must have a doctorate degree in Medicine, Osteopathy, Veterinary Medicine or one of the sciences, must have completed a postdoctoral fellowship, have been Principal Investigator on grants from the Scleroderma Foundation or other national, private or government agencies in the past.
Investigators who have questions about eligibility should contact the Scleroderma Foundation (see below).
Mechanism of Support: Applicants may request up to $75,000 (Up to 8% of the Direct Costs per year of award may be set aside as indirect costs. The indirect cost amount will be subtracted from the yearly total [up to $75,000) of the award) per year for up to two years (total for 2 years not to exceed $150,000). These awards are not renewable. Before completion of this grant, investigators are encouraged to seek more substantial continuing support for research through other grant mechanisms through private or government agencies. Replacement of the Principal Investigator on this award is not permitted. There will be no routine escalation for future years.
Awards are contingent on the availability of funds and the receipt of sufficiently meritorious applications meeting the stated eligibility requirements.
Research Objectives: The Scleroderma Foundation Innovative Grant is designed to facilitate highly innovative or highly relevant and meritorious pilot projects by established investigators in areas of research related to SSc that will culminate in more substantial funding from Federal or non-federal granting agencies such as the National Institutes of Health, National Science Foundation and the Department of Defense or Veterans Affairs.
Appropriate research areas may include but are not limited to the following as they relate to scleroderma:
Vascular manifestations. Studies of animal models. Therapeutic modalities. Mechanisms of end organ damage. Immunologic studies. Endothelial cell biology. Fibroblast biology. Models and markers of gender and genetic factors. Cell signaling. Epidemiology studies. Matrix biology. Stem cell biology. Health services research (e.g. quality of life, health care delivery.) Study of clinical manifestation.
Scleroderma Foundation 300 Rosewood Drive, Suite 105 Danvers, MA 01923
Phone: (978) 463-5843 (8:30 a.m. to 5 p.m. ET, Monday through Friday) Fax: (978) 463-5809 Toll-free: (800) 722-HOPE (4673)
Pediatric Orthopaedic Society of North America Research Award
A broad range of research areas will be considered for the POSNA Research Award, including patient based studies, basic science research, and multi-center or society wide projects. Pilot projects, research with pre-existing funding that may need supplemental support, as well as complete research proposals will be considered for funding. Research grant budgets should be detailed for one year and range from $1,000 to $30,000. Grants will be awarded based on an assessment of the scientific quality, importance of the research to the mission of POSNA, and ability of the work to help in the establishment of new areas of research, or new researchers from within the POSNA membership.
Applications are due October 19 and will be adjudicated by the POSNA Research Committee.
Applicants may apply for both the POSNA Research Award and the Kuo Award but must complete both applications.
You can contact the POSNA office at (847)698-1692 or e-mail at posna@aaos.org
International Society for Infectious Diseases Small Grants Program
The Small Grants Program is designed to fund pilot research projects by young investigators in developing countries. The goal is to support and foster the professional development of young individuals in the field of infectious diseases research by helping them to acquire additional skills and data to apply for other grants. Areas of interest include, but are not limited to investigations of the epidemiology, pathophysiology, diagnosis or treatment of infectious diseases, the epidemiology and control of hospital-acquired infections, and modeling of cost effective interventions.
Proposals will be reviewed by members of the Professional Development Working Group and decisions made in collaboration with the President and the Program Director.
Upon completion of the project, a written report of the project must be sent to the Society. The Society encourages recipients of grants to present their results at scientific meetings and to submit them for publication in peer-reviewed journals.
Deadlines Up to five grants of up to US $6,000 each will be awarded annually. Deadlines for submission of proposals are April 1 (notification after June 1) and October 1 (notification after December 1).
Requests for application materials and additional information should be directed to:
ISID Professional Development Working Group 1330 Beacon Street, Suite 228 Brookline, Massachusetts 02446 USA
Fax: (617) 731-1541 E-mail: info@isid.org
12next
